tazemetostat

GPTKB entity

Statements (39)
Predicate Object
gptkbp:instanceOf gptkb:drug
small molecule
gptkbp:approvalYear 2020
gptkbp:approvedBy gptkb:FDA
gptkbp:ATCCode L01XX71
gptkbp:brand gptkb:Tazverik
gptkbp:CASNumber 1403254-99-8
gptkbp:chemicalClass gptkb:pyridone
benzamide
gptkbp:developer gptkb:Epizyme,_Inc.
gptkbp:hasMolecularFormula C34H44N4O4
gptkbp:hasSMILES CC1=CC(=O)N(C2=CC=CC=C12)C3=CC=C(C=C3)NC(=O)C4=CC=C(C=C4)C(C)(C)C5=CC=C(C=C5)C(C)(C)C
https://www.w3.org/2000/01/rdf-schema#label tazemetostat
gptkbp:KEGGID D10813
gptkbp:legalStatus prescription only
gptkbp:mechanismOfAction EZH2 inhibitor
gptkbp:molecularWeight 572.74 g/mol
gptkbp:pregnancyCategory Not recommended
gptkbp:PubChem_CID gptkb:DB12983
gptkb:CHEMBL3137347
46209410
gptkbp:routeOfAdministration oral
gptkbp:sideEffect gptkb:anemia
nausea
vomiting
constipation
fatigue
cough
decreased appetite
pyrexia
gptkbp:synonym gptkb:E7438
gptkb:EPZ-6438
gptkbp:target gptkb:EZH2
gptkb:EZH1
gptkbp:UNII 6J8OL8451O
gptkbp:usedFor epithelioid sarcoma
follicular lymphoma
gptkbp:bfsParent gptkb:EZH2
gptkbp:bfsLayer 7